

# **Antibacterial chemotherapeutics 2**

## 1. $\beta$ -lactame antibiotics

### 1.1 Penicillins

### 1.2 Cephalosporins


## 2. Macrolide antibiotics

## 3. (Poly)peptide antibiotics

## 4. Aminoglycoside antibiotics


# $\beta$ -lactame antibiotics

**Lactams** = internal amides of amino acids




6-aminohexanoic acid  
 $\epsilon$ -aminocaproic acid


azepan-2-on  
 $\epsilon$ -caprolactam  
6-hexanlactam



piperidin-2-on  
 $\delta$ -valerolactam  
5-pentanlactam




pyrrolidin-2-on  
 $\gamma$ -butyrolactam  
4-butanlactam




azetidin-2-on  
 $\beta$ -propiolactam  
3-propanlactam

# $\beta$ -lactame antibiotics



## Penicillins

N-acyl-6-aminopenicillanic acids



## Cephalosporins

N-acyl-7-aminocephalosporanic acids

## Mechanism of action

- inhibition of cell wall synthesis by binding to specific proteins

# Penicilins History

## World

1928(9) – **Alexander Fleming** – isolated a liquid concentrate inhibiting growth of bacteria from a mould of *Penicillium* species

1939 - 1943 Fleming, Florey, Chain & Johnson – isolation and constitution of penicillins


1945-Nobel prize for Fleming, Florey and Chain

## Czech territory

1943 – Málek, Fragner, Herold, Hais etc. – Mykoin BF 510


# Penicillins

The initial „amorphous penicillin“ was a mixture of several compounds:




# Penicillins

## Benzylpenicillin and its problems




- production of benzylpenicillin by the mould  $\uparrow$  by addition of phenylacetic acid into its broth
- weak binding to plasmatic proteins  $\Rightarrow$  fast excretion  $\Rightarrow$  frequent administration is necessary
- instability in acid media of stomach (see reaction scheme)  $\Rightarrow$  impossibility of p.o. application



# Penicillins

## Benzylpenicillin and its problems

3. Sensitivity to penicillinases ( $\beta$ -lactamases – enzymes catalysing hydrolytic cleavage of the  $\beta$ -lactame ring ) – see the scheme




4. Rel. narrow spectrum – only  $G^+$  strains (*Streptococcus*, *Staphylococcus*, *Clostridium*, *Neisseria*, *Corynebacterium*, *Bacillus anthracis* ...)

5. Inducing allergies – anaphylactic shock – caused by 6-aminopenicillanic acid as the impurity – resolved by better purification (chromatography)


# Penicillins

## Resolving of benzylpenicillin problems

Ad 1. (necessity of frequent application) – poorly soluble salts with organic bases



**benzathine benzylpenicillin**  
Pendepon® inj. sic.



**procaine benzylpenicillin**  
Prokain Penicilin G® Biotika inj. sic.


•depot (= long acting) forms for i.m. injections



# Penicillins

## Resolving of benzylpenicillin problems

Ad 2. – ↑ of stability in acid media



### **phenoxymethylpenicillin** syn. **penicillin V**



- acquired by addition of phenoxyacetic acid into the broth of the production strain
  - suitable for p.o. administration  
V-Penicilin®, Ospen®

# Penicillins

Overall resolving of benzylpenicillin problems – **semi-synthetic penicillins**

• **penicillinamidase (penicillinacylase)** – hydrolyzes acyclic amide bond, not  $\beta$ -lactame ring


• used a microbe which produces it (e.g. *E. coli*)



# Penicillins


## Mostly semi-synthetic penicillins stable in acid media

- stability against acids is increased by electron-donor substituents in N-acyl side chain (I+ or M+ efekt)



### **ampicillin**

Ampicilin<sup>®</sup> cps., inj sic.



R = -H

V-Penicilin<sup>®</sup> tbl., Oспен tbl. obd.

R = -CH<sub>3</sub>

R = -CH<sub>2</sub>CH<sub>3</sub>

**phenoxymethylpenicillin**


**phenethicillin**

**propicillin**


# Penicillins

## Semi-synthetic penicillins resistant to $\beta$ -lactamases

- formed by acylation of amino group of 6-aminopenicillanic acid with bulky acyl rest; the lactame ring is then sterically hindered ( $\Rightarrow$  protected)



**meticillin**



$R^1 = R^2 = -H$       **oxacillin**

Prostaphlin<sup>®</sup> eps., inj. sic.

$R^1 = -Cl, R^2 = -H$       **cloxacillin**

$R^1 = R^2 = -Cl$       **dicloxacillin**

$R^1 = -Cl, R^2 = -F$       **flucloxacillin**

syn. floxacillin [USAN]


- resistant also to acid media; the resistance increases  
oxacillin < cloxacillin < dicloxacillin = flucloxacillin

# Penicillins

An alternative approach to ↑ of resistance to  $\beta$ -lactamases:


## $\beta$ -lactamases inhibitors

- compounds with  $\beta$ -lactam ring which binds to the enzyme active site with greater affinity and block this site
- used in combination with penicillins



### **clavulanic acid**


- isolated from *Streptomyces clavuligerus*
- + amoxicillin (= Amoxiklav<sup>®</sup>, Augmentin<sup>®</sup>)
- + ticarcillin (= Timentin<sup>®</sup> inj. sic.)



### 4,4-dioxopenicillanic acid

### **sulbactam**

- Betrimon<sup>®</sup>
- + ampicillin (= Ampisucillin<sup>®</sup> inj. plv. sol.)




### **tazobactam**

- + piperacillin (= Tazocin<sup>®</sup> inj. sic.)

## Penicillins

A combination of a penicilline with a  $\beta$ -lactamase inhibitor in one molecule



- a mixed ester of ampicillin and sulbactam with methanediol
- a prodrug of both components

### **sultamicillin**


Bitamon<sup>®</sup> inj. sic., Unasyn<sup>®</sup> tbl. obd.

# Penicillins

## Penicillins with broadened spectrum

Ad 4. – introduction of a hydrophilic substituent to  $\alpha$ -position of the acyl attached to amino group of 6-aminopenicillanic acid  $\Rightarrow$  **broadening of the antibacterial spectrum of penicillins also to G<sup>-</sup> strains**


Compounds with free primary amino group



R = -H **ampicillin**



R = -OH **amoxycillin**

Amoclen<sup>®</sup>, Amopen<sup>®</sup>



**epicillin**

## Penicillins with broadened spectrum Ampicillin prodrugs



- hydrolyzed *in vivo* to ampicillin
- achieve significantly higher blood and tissue levels and attains peak blood levels more rapidly than equimolar doses of oral ampicillin
- more frequently used in veterinary (horses) than in human medicine
- models for design of prodrugs of cephalosporins

### **bacampicillin**

ampicillin 1-(ethoxycarbonyloxy)ethylester

### **pivampicillin**

ampicillin pivaloyloxymethylester


- successful in acute exacerbations of chronic bronchitis



## Penicillins with broadened spectrum: ureidopenicillins


Compounds in which the amino group in  $\alpha$ -position of the acyl is a part of urea moiety = **ureidopenicillins** = „anti-pseudomonas“ penicillins

•their spectrum includes *Pseudomonas aeruginosa*



**piperacillin**

Tazocin<sup>®</sup> inj. plv. sol.(+ tazobactam)



R = H-

**azlocillin**


R = CH<sub>3</sub>SO<sub>2</sub>-

**mezlocillin**


•serious infections including *otitis media*, CNS infections ...

## Penicillins with broadened spectrum:

- compounds with the additional carboxyl in  $\alpha$ -position of the acyl attached to amino group in position 6
- in fact substituted malonic acids monoamides



**carbenicillin**






**ticarcillin**

Timentin<sup>®</sup> inj. sic. (+ clavulanic acid)  
• infections of bones and junctures  
(*Staphylococcus aureus*),  
gynecological & abdominal infections ...

- ring analogy (benzene – thiophene)

# Cephalosporins


- fungi *Cephalosporium spp.* (1948)




... and other various structures

# Cephalosporins


## General structure



cephalosporin C  
•isolated from *Cephalosporium spp.*




cephamycin C  
•isolated from *Streptomyces lactadurans*



# Cephalosporins



## Properties



- electron pair on N5 is linked to conjugation with double bond  $\Rightarrow$   $\downarrow$  of electron density on N5  $\Rightarrow$   $\downarrow$  of nucleophilicity of N5  $\Rightarrow$  stability in acid media
- also  $\uparrow$  resistance to  $\beta$ -lactamases (cephalosporinases)

## Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid.




\* glutarylacylase + D-amino acid oxidase

## Cephalosporins


Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

1<sup>st</sup> generation: for parenteral administration only (not absorbed from GIT)



**cephalotin**

Cefalotin<sup>®</sup> Biotika inj. sic.




**cefaloridin**

# Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

2<sup>nd</sup> generation: for oral administration



R<sup>1</sup>= -H, R<sup>2</sup>= -CH<sub>3</sub>

**cefalexin**

Cefaclen<sup>®</sup> cps.

R<sup>1</sup>= -OH, R<sup>2</sup>= -CH<sub>3</sub>

**cefadroxil**

Biodroxil<sup>®</sup> tbl. obd.

R<sup>1</sup>= -H, R<sup>2</sup>=Cl

**cefaklor**


Ceclor<sup>®</sup> cps.



## Cephalosporins


Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

2<sup>nd</sup> generation: for parenteral use but with ↑ effect to G<sup>-</sup>, ↑ resistance to β-lactamases



**cefazolin**

Kefzol® inj. sic.




**cefsulodin**

•*Pseudomonas*


# Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

**2<sup>nd</sup> generation:** for both parenteral and p.o. administration, very resistant to  $\beta$ -lactamase




**cefamandole**



R = H-

**cefuroxime**

Ceroxim<sup>®</sup> tbl.




**cefuroxime axetil**

Zinnat<sup>®</sup> tbl. obd.

# Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid


3<sup>rd</sup> generation: for both parenteral and p.o. administration, very resistant to  $\beta$ -lactamase



**cefotaxime**

Claforan<sup>®</sup> inj. sic.


R = H- **cefpodoxime**



# Cephalosporins


Compounds related to **cephamycin C**, i.e. N-acylderivatives of 7-methoxy-7-aminocephalosporanic acid

„New class = 4<sup>th</sup> generation“ – for both parenteral and p.o administration – resistant to  $\beta$ -lactamase




**cefoxitin**

Mefoxin<sup>®</sup> inj. sic.



**cefminox**

## Cephalosporin analogues



### **moxalactam**


- dihydrooxazine derivative related to 4<sup>th</sup> generation of cephalosporins
- developed especially for treatment of meningitis (crosses the blood-brain barrier) and anaerobic infections

## Macrolides

- makrocyclic lactones with 10 – 40membered ring with 1 aminomonosaccharide and 1 „neutral“ monosaccharide which can have an additional aminosaccharide attached
- 1<sup>st</sup> group (with larger ring)- natamycine, nystatine, amphotericine B – see antimycotics
- 2<sup>nd</sup> group – **erythromycine group** (erythromycine and its analogues, spiramycine, tylosine)

### Common structure of narrower group of erythromycine

(14 -15membered laktone ring - erythromycine and analogues)



R<sup>1</sup>= -OH, -H

Z =  $\text{>C=O}$ ,  $-\text{CH}_2\text{N}(\text{CH}_3)-$ ,  $\text{>C=N-O-CH}_3$ ,  $\text{>C=NOCH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$


R<sup>2</sup>= -H, -F

R<sup>3</sup>= -H, -CH<sub>3</sub>

R<sup>4</sup>= -CH<sub>3</sub> or R<sup>2</sup> + R<sup>4</sup>= oxirane

# Macrolides

## Site & mechanism of action



# Macrolides

## Site and mechanism of action

- **Proteosynthesis inhibition**

- act at 50S ribosome subunit

- inhibit the translocation of growing peptide from acceptor (A) to peptide (P) site

- **bacteriostatic effect**

Spectrum:


- both G<sup>+</sup> and G<sup>-</sup>

*Neisseria, Haemophilus, Brahmanella, Legionella ...*




# Macrolides

## Erythromycine and its analogues



### erythromycine

- isolated 1952 from *Streptomyces erythreus*
- poor biological availability  $\Rightarrow$  lipophilic salts (stearate, ethylsuccinate ...)
- external form (lotions ...) – treatment of *acne vulgaris*  
Porphyrocine<sup>®</sup> tbl.




### azithromycine

- semi-synthetic compound  
Sumamed<sup>®</sup> tbl. o.b.d.


# Macrolides

## Synthesis of azithromycin from erythromycin




## Macrolides

Erythromycin and its analogues



6-O-methylerythromycin  
**clarithromycin**


•also some strains of *Mycobacterium avium*  
Klacid<sup>®</sup> tbl. obd.




**roxithromycin**  
Rulid<sup>®</sup> tbl.

## Macrolides

Erythromycin and its analogues




8-fluoroerythromycin  
flurithromycin



dirithromycin


# Macrolides

## Erythromycine and its analogues



### oleandomycine


•isolated 1954 from *Streptomyces antibioticus*



### lexithromycine


„More free“ erythromycin analogues: **Ketolides**

- 2 keto-moieties on lactone ring (+ 1 ester carbonyl + 1 carbamate carbonyl)
- good biological availability



# Macrolides

Compounds with 16membered lactone ring unsaturated in positions 10 and 12



•isolated 1954 from *Streptomyces ambofaciens*

R = HCO- spiramycine A = spiramycine I

CH<sub>3</sub>CO- spiramycine B = spiramycine II

CH<sub>3</sub>CH<sub>2</sub>CO- spiramycine C = spiramycine III

Rovamycine® tbl. obd.


## josamycin

•also *Mycoplasma*

Wilprafen® tbl. obd., Alpucine®  
premix a.u.v.


# Macrolides

Compounds with 16membered lactone ring unsaturated in positions 11 and 13



**rokitamycin**

**miokamycin**






## (Poly)peptide antibiotics


- site of action: cytoplasmic membrane
- mode of action: ionophores: cause uncontrolled exchange of ions between inside and outside media of a bacterial cell and thus ionic imbalance and cell death
- very toxic, external application
- totally known approx. 200 ATB of polypeptid structure
- homomeric peptides: contain amino acids only (often D-)
- heteromeric peptides: except amino acids also other carboxylic acids
- if they are cyclic, then homodets and heterodets

# Tyrothricin

- mixture from *Brevibacillus brevis*




tyrocidin A  
tyrocidins A – E total 80%  
decapeptides



gramicidin A<sub>1</sub>  
20 % of gramicidins A<sub>1</sub>, A<sub>2</sub>, C<sub>1</sub> and C<sub>2</sub>  
pentadecapeptides

# Polymyxins and colistins




polymyxin B

colistin A: D-Leu instead D-Phe

# Bacitracin

L-Ile



## **bacitracin A**

Framykoin<sup>®</sup> ung., Pamycon<sup>®</sup> plv. (+ neomycin B)

# Aminoglycosides

- aminosaccharide glycosides produced by strains of *Streptomyces* genus
- Streptomycin group
- Neomycin group
- Kanamycin and gentamycin group

## Mechanism of action

- **proteosynthesis inhibition**
- they avoid accurate reading of the genetic code and binding of peptidyl-tRNA to the peptide binding site
- **effect bacteriostatic – bactericidal**


## Spectrum

**G<sup>+</sup> < G<sup>-</sup>**

*Bacillus anthracis, Bordetella pertussis, Brucella, Corynebacterium diphtheriae, E. coli, Enterobacter, Haemophilus, Mycobacterium tuberculosis...*

# Aminoglycosides

## 1. Streptomycin group



R = -CHO

**streptomycin**

•isolated 1944 from *Streptomyces fradiae*

•used to *M. tuberculosis* in combination with other tuberculostatics

•bactericidal

Streptomycin „Grünenthal“<sup>®</sup> inj. sic., Streptowerfft<sup>®</sup> a.u.v


R = -CH<sub>2</sub>OH

**dihydrostreptomycin**

Depomycine<sup>®</sup> a.u.v. inj. (+ benzylpenicillin)

# Aminoglycosides

## 2. Neomycin group



R = -NH<sub>2</sub> **neomycin B**

•mixture of neomycins isolated from *Streptomyces fradiae* in 1949

Framykoin® ung., Pamycon® plv. (+ bacitracin)

R = -OH **paromomycin**

•not absorbed from GIT


•used for *Entamoeba histolytica*

Humatin® cps.


# Aminoglycosides

## 3. Group of kanamycin and gentamicin

### Kanamycin subgroup




R = -H **kanamycin**  
Kanacol® a.u.v. inj.



### **tobramycin**

Tobi Nebuliser Solution®  
inh. sol.


•treatment of chronic pulmonary infection caused by *Pseudomonas* in patients with cystic fibrosis





# Aminoglycosides




## 3. Group of kanamycin a gentamycin Subgroup of gentamycin



R<sup>1</sup>= H-

H-

CH<sub>3</sub>CH<sub>2</sub>-



### gentamycin

Garasone® gtt. opht.  
(+betamethason)  
Diagen® a.u.v.

### sisomycin

### netilmycin

Netromycine® inj.  
•serious infections,  
sepsis ...